

Comments from Mattias Perjos, President & CEO

Strong order intake and our remediation measures completed in Germany

“Organic order intake increased by more than 20% in the third quarter, with a strong performance in all business areas and regions. Order growth was strong compared with both 2019 and 2020. As expected, net sales declined year on year as we had record-breaking deliveries of ICU ventilators in Q3 2020. Compared with Q3 2019, sales increased significantly as a result of continuing high demand for our products for life supporting ECMO therapy, bioreactors and products for Sterile Transfer, combined with continuing high sales of ventilators and a general recovery in other areas of the business. Surgical Workflows is the only business area whose sales were just under the level of Q3 2019. This is due to the slower conversion of orders to net sales because of longer lead times in this business coupled with limited capacity for hospitals to receive deliveries due to COVID-19. However, order intake for Surgical Workflows has strengthened at a fast pace, which is positive for 2022. Growth for our products for planned cardiovascular procedures softened in the quarter as a result of the spread of the Delta variant in parts of the US, and we cannot rule out temporary regional volume declines in these product categories in Q4 due to the spread of the virus.

We achieved a milestone during the quarter when we completed our remediation measures under the Consent Decree with the FDA at our production site in Hechingen, Germany. This does not mean that we automatically are out of the Consent Decree, but that all production sites covered by the Consent Decree can focus all their energy on forward-looking activities related to customer value and growth. Our underlying EBITA margin excluding COVID-19 effects continues to improve due to structural mix shift and enhanced productivity. We successfully avoided cost increases and delays in the supply chain during the quarter but we may be impacted if the situation were to deteriorate over the next few quarters. Our cash flow remains strong, meaning that we have strengthened our solid financial position. We are continuing to implement our strategy – focusing on product development, growth and profitability – according to plan. For example, we launched Rotaflow II during the quarter, the latest addition to our advanced life supporting solutions. Finally, I would like to thank our customers and employees for the great collaboration in the quarter!”

July – September 2021 in brief

- The order intake increased organically by 21.8% and net sales declined organically by 20.1%.
- Adjusted gross profit amounted to SEK 3,334 M (4,378) and the gross margin was 52.9% (54.9).
- Adjusted EBITA amounted to SEK 1,160 M (2,028) and the EBITA margin was 18.4% (25.4).
- Adjusted earnings per share amounted to SEK 2.96 (5.37).
- Cash flow after net investments amounted to SEK 1,380 M (1,567).

January – September 2021 in brief

- The order intake declined organically by 5.8% and net sales declined organically by 2.8%.
- Adjusted gross profit amounted to SEK 10,242 M (11,318) and the gross margin was 53.7% (53.9).
- Adjusted EBITA amounted to SEK 3,489 M (3,907) and the EBITA margin was 18.3% (18.6).
- Adjusted earnings per share amounted to SEK 8.68 (9.85).
- Cash flow after net investments amounted to SEK 4,634 M (3,924).

Outlook 2021

For 2021, Getinge estimates that sales will amount to a minimum of SEK 27 billion. Information about Getinge’s outlook for the next few years will be presented at the Capital Markets Day on November 22.

Summary of financial performance¹⁾

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Order intake	7,079	5,898	20,629	23,431	30,568
Organic change, %	21.8	-5.3	-5.8	19.1	15.6
Net sales	6,306	7,976	19,061	20,980	29,819
Organic change, %	-20.1	33.4	-2.8	15.9	14.3
Adjusted gross profit	3,334	4,378	10,242	11,318	15,874
Margin, %	52.9	54.9	53.7	53.9	53.2
Adjusted EBITDA	1,547	2,455	4,636	5,200	7,487
Margin, %	24.5	30.8	24.3	24.8	25.1
Adjusted EBITA	1,160	2,028	3,489	3,907	5,724
Margin, %	18.4	25.4	18.3	18.6	19.2
Adjusted EBIT	1,092	1,915	3,287	3,537	5,261
Margin, %	17.3	24.0	17.2	16.9	17.6
Operating profit (EBIT)	1,094	1,913	3,259	3,175	4,784
Margin, %	17.4	24.0	17.1	15.1	16.0
Profit before tax	1,052	1,841	3,112	2,944	4,485
Net profit for the period	767	1,395	2,225	2,169	3,273
Adjusted net profit for the period	815	1,478	2,392	2,707	3,965
Margin, %	12.9	18.5	12.5	12.9	13.3
Adjusted earnings per share, SEK	2.96	5.37	8.68	9.85	14.43
Earnings per share, SEK	2.78	5.07	8.07	7.88	11.89
Cash flow from operating activities	1,495	1,773	4,990	4,656	7,199

1) See page 3 for calculations of adjusted performance measures.

Group performance

Order intake

July – September 2021

Order intake business areas, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Acute Care Therapies	3,830	3,285	18.6	11,416	15,504	-20.5	19,208
Life Science	905	701	29.6	2,813	2,178	36.7	3,413
Surgical Workflows	2,344	1,912	24.6	6,400	5,749	17.6	7,948
Total	7,079	5,898	21.8	20,629	23,431	-5.8	30,568

Order intake regions, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Americas	2,778	2,260	25.7	7,759	8,974	-5.0	11,601
APAC	1,829	1,257	46.7	5,249	5,074	10.2	6,603
EMEA	2,472	2,381	5.0	7,621	9,383	-15.3	12,364
Total	7,079	5,898	21.8	20,629	23,431	-5.8	30,568

Net sales


July – September 2021

Net sales business areas, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Acute Care Therapies	3,592	5,310	-31.6	11,297	13,327	-8.6	18,719
Life Science	866	746	17.5	2,515	2,048	30.0	2,854
Surgical Workflows	1,847	1,920	-2.9	5,250	5,605	-1.2	8,246
Total	6,306	7,976	-20.1	19,061	20,980	-2.8	29,819

Net sales regions, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Americas	2,578	2,940	-10.9	7,551	8,156	1.7	11,394
APAC	1,589	1,669	-3.7	4,479	4,378	8.8	6,329
EMEA	2,139	3,367	-36.3	7,031	8,446	-13.3	12,096
Total	6,306	7,976	-20.1	19,061	20,980	-2.8	29,819

Net sales specified by capital goods & consumables, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Capital goods	2,654	4,543	-41.2	8,288	10,335	-14.6	15,473
Consumables	3,652	3,434	7.8	10,773	10,645	8.5	14,346
Total	6,306	7,976	-20.1	19,061	20,980	-2.8	29,819

Net sales – bridge between Q3 2020 and Q3 2021



- All business areas and regions reported a strong organic increase in order intake.
- Order intake remained high in ventilators and ECMO therapy products in Acute Care Therapies and for bioreactors and Sterile Transfer products in Life Science. Surgical Workflows increased its order intake in all categories, with particularly positive growth in OR products.
- Americas and APAC are growing due to healthy growth in all business areas, while growth in EMEA was slightly lower as a result of challenging comparative figures for ventilators in Q3 2020.

- Life Science is continuing to increase its sales in Sterile Transfer and bioreactors organically in all regions for research and production of vaccines and biopharmaceutical drugs.
- The decline in net sales for Acute Care Therapies was attributable to challenging comparative figures in Q3 2020 as a result of record-breaking deliveries of advanced ICU ventilators. Sales of cardiovascular surgery products were higher for the quarter, but the spread of the Delta variant in parts of the US impeded growth slightly. The spread also led to continuing high sales of ventilators and ECMO therapy products.
- Net sales for Surgical Workflows declined slightly organically as a result of lower order bookings at the start of the quarter and temporary restrictions on customers receiving deliveries due to COVID-19.

- Net sales declined by SEK 1,670 M, corresponding to -20.9%.
- Net sales for Quadralene, which was acquired at the end of 2020, accounted for SEK 11 M, corresponding to 0.1%.
- Exchange rates had an impact of SEK -77 M on sales, corresponding to -0.9%.
- Volumes, mix and price had an impact of SEK -1,604 M on sales, corresponding to -20.1%.

- Currency effects impacted adjusted gross profit by SEK -46 M and adjusted EBITA by SEK -64 M.
- The gross margin declined as a result of lower volumes and thus lower use of capacity in production. However, the implemented productivity-enhancing measures offset this effect.
- Adjusted operating expenses fell by 7.1% compared with Q3 2020. Expenses fell organically by 8.5%.
- Adjusted EBITA fell by SEK 868 M compared with the year-earlier period (which was affected by record-breaking deliveries of ventilators), resulting in a margin of 18.4%.
- Acquisition and restructuring costs and other items affecting comparability were marginal for the quarter.
- Net financial items improved SEK 29 M as a result of lower net debt and interest expenses.
- The effective tax rate was about 27%, which is slightly lower than earlier in the year and was due to healthy earnings in the Swedish part of the operations.

Underlying earnings trend

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Net sales	6,306	7,976	19,061	20,980	29,819
Adjusted gross profit	3,334	4,378	10,242	11,318	15,874
Margin, %	52.9	54.9	53.7	53.9	53.2
Adjusted operating expenses	-1,787	-1,923	-5,606	-6,118	-8,387
Adjusted EBITDA	1,547	2,455	4,636	5,200	7,487
Margin, %	24.5	30.8	24.3	24.8	25.1
Depreciation, amortization and write-downs of intangible assets and tangible assets ¹⁾	-387	-427	-1,147	-1,293	-1,763
Adjusted EBITA	1,160	2,028	3,489	3,907	5,724
Margin, %	18.4	25.4	18.3	18.6	19.2
A Amortization and write-down of acquired intangible assets ¹⁾	-68	-113	-201	-370	-463
Adjusted EBIT	1,092	1,915	3,287	3,537	5,261
Margin, %	17.3	24.0	17.2	16.9	17.6
B Acquisition and restructuring costs	3	-2	-100	-172	-177
C Other items affecting comparability ²⁾	-	-	72	-190	-300
Operating profit (EBIT)	1,094	1,913	3,259	3,175	4,784
Net financial items	-43	-72	-147	-230	-299
Profit before tax	1,052	1,841	3,112	2,944	4,485
Adjusted profit before tax (adjusted for A, B and C)	1,117	1,956	3,342	3,677	5,425
Margin, %	17.7	24.5	17.5	17.5	18.2
Taxes	-285	-446	-887	-775	-1,213
D Adjustment of tax ²⁾	-17	-32	-64	-194	-248
Adjusted net profit for the period (adjusted for A, B, C and D)	815	1,478	2,392	2,707	3,965
Margin, %	12.9	18.5	12.5	12.9	13.3
Of which, attributable to Parent Company shareholders	805	1,463	2,364	2,683	3,931
Average number of shares, thousands	272,370	272,370	272,370	272,370	272,370
Adjusted earnings per share, SEK (adjusted for A, B, C and D)	2.96	5.37	8.68	9.85	14.43

1) Excluding items affecting comparability (see Note 3 for depreciation, amortization and write-downs).
2) See Note 5.


- Acute Care Therapies reduced its adjusted EBITA by SEK 1,027 M, mainly due to lower volumes related to ventilators. This also contributed to a lower margin.
- Life Science's adjusted EBITA rose by SEK 71 M and the margin increased by 5.6 percentage points, mainly due to higher sales volumes, a positive mix and lower operating expenses.
- Surgical Workflows' adjusted EBITA improved by SEK 76 M compared with Q3 2020 and the margin improved by 4.1 percentage points. This was despite continuing lower volumes than last year.

Adjusted EBITA per business area¹⁾

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Acute Care Therapies	963	1,990	3,243	4,178	5,831
Margin, %	26.8	37.5	28.7	31.3	31.1
Life Science	207	136	508	281	393
Margin, %	23.9	18.3	20.2	13.7	13.8
Surgical Workflows	66	-10	-3	-283	-127
Margin, %	3.6	-0.5	-0.1	-5.0	-1.5
Group functions and other (incl. eliminations)	-76	-88	-259	-269	-374
Total	1,160	2,028	3,489	3,907	5,724
Margin, %	18.4	25.4	18.3	18.6	19.2

1) See Note 3 for depreciation and write-downs and Note 5 for other items affecting comparability.

Adjusted EBITA – bridge between Jul-Sep 2020 and Jul-Sep 2021



Adjusted operating expenses

(excluding depreciation, amortization and write-downs and other items affecting comparability)¹⁾

- Adjusted operating expenses fell by 7.1% compared with Q3 2020. Organically, the decline was 8.5% compared with last year, a result of a continuing low cost level due to COVID-19.

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Selling expenses	-971	-1,030	-2,946	-3,275	-4,497
Administrative expenses	-706	-739	-2,172	-2,319	-3,048
Research and development costs	-186	-195	-581	-588	-770
Other operating income and expenses	76	40	94	64	-72
Total	-1,787	-1,923	-5,606	-6,118	-8,387

1) See Note 3 for depreciation and write-downs and Note 5 for other items affecting comparability.

- Adjusted gross profit was impacted by translation effects of SEK -39 M and transaction effects and hedging outcome of SEK -7 M.
- Adjusted EBITA was impacted by translation effects of SEK -7 M and the net of transaction effects, hedging outcome and revaluation of operating receivables and liabilities in foreign currency (impacting other operating income and expenses) of SEK -57 M.

Currency impact

SEK M	Jul-Sep 2021	Jan-Sep 2021
Net sales	-77	-1,357
Adjusted gross profit	-46	-835
Adjusted EBITDA	-69	-452
Adjusted EBITA	-64	-395
Adjusted EBIT	-63	-377

- Cash flow after net investments remained strong, mainly due to positive operating profit. This contributed positively to changes in working capital.
- Net debt was positively affected by the strong cash flow, and net debt in relation to adjusted EBITDA R12M continued to improve compared with the same period last year.

Cash flow and financial position¹⁾

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Cash flow before changes in working capital	1,255	2,197	3,840	4,354	6,352
Changes in working capital	240	-424	1,150	302	847
Net investments in non-current assets	-115	-206	-357	-732	-993
Cash flow after net investments	1,380	1,567	4,634	3,924	6,207
Net interest-bearing debt			4,134	9,946	7,509
<i>In relation to adjusted EBITDA¹⁾ R12M, multiple</i>			0.6	1.4	1.0
Net interest-bearing debt, excl. pension provisions			901	6,320	4,150
<i>In relation to adjusted EBITDA¹⁾ R12M, multiple</i>			0.1	0.9	0.6

1) See Note 5 for items affecting comparability and Note 7 for alternative performance measures.

- Amortization and write-downs related to R&D fell by SEK 48 M compared with the preceding year.
- Capitalized development costs declined SEK 6 M or 6.7% compared with the year-earlier period.

Research and development

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
R&D costs, gross	-284	-297	-875	-1,077	-1,462
<i>In relation to net sales, %</i>	4.5	3.7	4.6	5.1	4.9
Capitalized development costs	84	90	258	318	429
<i>In relation to net sales, %</i>	1.3	1.1	1.4	1.5	1.4
Research and development costs, net	-200	-207	-617	-759	-1,033
Amortization and write-downs of capitalized R&D	-98	-146	-288	-544	-783
<i>Of which write-downs</i>	-5	-7	-5	-123	-206

Acute Care Therapies

Acute Care Therapies offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures and a broad selection of products and therapies for intensive care. The addressable market, excluding the effects of the COVID-19 pandemic, amounts to SEK 85 billion with expected long-term organic growth of 2-4% per year.

- Significant organic order growth for the quarter in ventilators and ECMO therapy products.
- Other product categories increased their order intake, despite growth in cardiovascular surgery products softening slightly in the quarter as a result of the spread of the Delta variant in parts of the US.

- The decline in sales was exclusively due to highly challenging comparative figures as a result of record-breaking deliveries of ventilators in Q3 2020.
- Continuing growth in products for ECMO therapy and cardiovascular procedures, although growth in the latter category softened slightly in the quarter as a result of the spread of the Delta variant in parts of the US.

Order intake and net sales

Order intake regions, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Americas	1,939	1,593	24.5	5,408	6,816	-12.5	8,483
APAC	967	643	52.0	2,847	3,181	-4.3	3,912
EMEA	924	1,049	-11.0	3,160	5,507	-39.6	6,814
Total	3,830	3,285	18.6	11,416	15,504	-20.5	19,208

Net sales regions, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Americas	1,771	2,227	-19.2	5,246	5,940	-2.7	8,431
APAC	927	994	-5.7	2,697	2,612	10.3	3,722
EMEA	894	2,089	-57.2	3,354	4,775	-26.3	6,566
Total	3,592	5,310	-31.6	11,297	13,327	-8.6	18,719

Net sales specified by capital goods & consumables, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Capital goods	1,029	2,915	-64.9	3,671	5,757	-31.7	8,593
Consumables	2,563	2,396	8.8	7,626	7,570	9.0	10,126
Total	3,592	5,310	-31.6	11,297	13,327	-8.6	18,719

Underlying earnings trend¹⁾

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Net sales	3,592	5,310	11,297	13,327	18,719
Adjusted gross profit	2,180	3,312	7,009	8,314	11,536
Margin, %	60.7	62.4	62.0	62.4	61.6
Adjusted EBITDA	1,168	2,226	3,859	4,905	6,833
Margin, %	32.5	41.9	34.2	36.8	36.5
Depreciation, amortization and write-downs of intangible assets and tangible assets	-205	-236	-616	-728	-1,002
Adjusted EBITA	963	1,990	3,243	4,178	5,831
Margin, %	26.8	37.5	28.7	31.3	31.1

¹⁾ See Note 3 for depreciation and write-downs and Note 5 for other items affecting comparability.

- The adjusted gross margin declined by 1.7 percentage points in relation to the year-earlier quarter, primarily as a result of lower volumes for ventilators. Effective production transition helped to reduce the effect of lower volumes slightly.
- Adjusted operating expenses fell by 6.9%. Organically expenses fell by 8.2% compared with Q3 2020, which was characterized by higher costs related to the record-breaking sales of ventilators.
- Lower sales volumes in ventilators contributed to the adjusted EBITA margin falling 10.7 percentage points compared with the preceding year. Enhanced productivity and product mix helped to reduce the negative effect slightly.
- Currency effects impacted sales by SEK -39 M, adjusted gross profit by SEK -27 M and adjusted EBITA by SEK -38 M.

Events in the business area

- In the quarter, Getinge completed its remediation measures in Hechingen, Germany, in accordance with the Consent Decree with the FDA. This does not automatically mean that Getinge is out of the Consent Decree, but that all entities covered by the Consent Decree (Hechingen and Rastatt in Germany and Merrimack and Wayne in the US) now can put all their efforts into forward-looking activities to add customer value and growth.
- Getinge introduced Rotaflow II, a new product for life support. The technology enables up to 14 days of ECMO therapy in a compact format, giving health care professionals the flexibility needed to provide quality patient care.

Life Science

Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research. The addressable market, excluding the effects of the COVID-19 pandemic, amounts to SEK 33 billion with expected long-term organic growth of 8–10% per year.

- Continued strong order growth in products for Sterile Transfer that are used in, for example, the production of vaccines. Strong growth in bioreactors from Applikon for the development and production of biopharmaceutical drugs. The order intake for service showed double-digit growth for the quarter.
- Significant growth in APAC, mainly due to strong performance in China.

- Continuing high organic sales growth in Sterile Transfer products, washer-disinfectors and bioreactors to meet rising demand for efficient and reliable technology for developing and manufacturing drugs.
- Net sales also increased in service and spare parts, albeit at a lower rate than in the categories above.
- Growth in all regions, with a particularly strong performance in Americas.

- The adjusted gross margin strengthened by 1.7 percentage points, as a result of higher volumes, a favorable mix and better absorption in production.
- Adjusted operating expenses fell by 2.7%. These expenses fell organically by 8.9% mainly due to lower sales overheads in the quarter and lower costs in other operating items.
- Increased sales volumes contributed to adjusted EBITA rising by SEK 71 M year-on-year. The margin improved to 23.9%.
- Currency effects impacted sales by SEK -10 M, adjusted gross profit by SEK -7 M and adjusted EBITA by SEK -16 M.

Order intake and net sales

Order intake regions, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Americas	325	289	14.5	927	918	9.5	1,336
APAC	188	85	114.6	695	319	130.1	558
EMEA	392	327	20.8	1,190	940	31.6	1,518
Total	905	701	29.6	2,813	2,178	36.7	3,413

Net sales regions, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Americas	347	265	33.6	973	831	27.1	1,103
APAC	165	159	3.8	441	341	36.1	473
EMEA	354	321	11.1	1,100	876	30.4	1,278
Total	866	746	17.5	2,515	2,048	30.0	2,854

Net sales specified by capital goods & consumables, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Capital goods	643	534	21.8	1,881	1,434	38.6	2,029
Consumables	223	212	6.8	634	614	10.1	825
Total	866	746	17.5	2,515	2,048	30.0	2,854

Underlying earnings trend¹⁾

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Net sales	866	746	2,515	2,048	2,854
Adjusted gross profit	384	318	1,080	856	1,176
Margin, %	44.3	42.6	42.9	41.8	41.2
Adjusted EBITDA	240	170	611	380	522
Margin, %	27.7	22.8	24.3	18.5	18.3
Depreciation, amortization and write-downs of intangible assets and tangible assets	-33	-33	-102	-98	-128
Adjusted EBITA	207	136	508	281	393
Margin, %	23.9	18.3	20.2	13.7	13.8

1) See Note 3 for depreciation and write-downs and Note 5 for other items affecting comparability.

Events in the business area

- Applikon delivered its largest vaccine production system to date to a Chinese vaccine producer. By the end of the quarter, net sales for production development systems already exceeded sales for the whole of 2019, which was a record-breaking year.
- The project to expand production capacity of DPTE BetaBags® in Merrimack, USA, is progressing according to plan. In addition, production capacity at Applikon is being expanded to meet the growing global demand for bioreactor systems.

Surgical Workflows

Surgical Workflows offers products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms. The addressable market, excluding the effects of the COVID-19 pandemic, amounts to SEK 62 billion with expected long-term organic growth of 2–4% per year.

- Sharp organic order growth in all regions (from low levels last year), meaning that order bookings are continuing to recover at a good pace.
- Growth was particularly high in Surgical Workplaces which includes OR products.

- Continuing negative trend in organic net sales, despite the order intake recovering. This was due to generally long lead times from order to delivery in the business area.
- The organization's focus on the customer offering for service and consumables is continuing to make a positive contribution to sales for the business area.

Order intake and net sales

Order intake regions, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Americas	515	378	39.3	1,423	1,239	26.1	1,782
APAC	673	529	29.4	1,707	1,574	15.1	2,134
EMEA	1,157	1,005	16.6	3,270	2,936	15.3	4,032
Total	2,344	1,912	24.6	6,400	5,749	17.6	7,948

Net sales regions, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Americas	460	448	4.1	1,332	1,386	5.4	1,860
APAC	497	515	-2.0	1,340	1,425	-0.5	2,133
EMEA	890	957	-6.7	2,577	2,794	-4.7	4,253
Total	1,847	1,920	-2.9	5,250	5,605	-1.2	8,246

Net sales specified by capital goods & consumables, SEK M	Jul-Sep 2021	Jul-Sep 2020	Org Δ, %	Jan-Sep 2021	Jan-Sep 2020	Org Δ, %	Jan-Dec 2020
Capital goods	981	1,094	-8.9	2,736	3,144	-7.4	4,851
Consumables	866	826	5.0	2,514	2,460	6.9	3,394
Total	1,847	1,920	-2.9	5,250	5,605	-1.2	8,246

Underlying earnings trend¹⁾

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Net sales	1,847	1,920	5,250	5,605	8,246
Adjusted gross profit	770	748	2,154	2,148	3,163
Margin, %	41.7	39.0	41.0	38.3	38.4
Adjusted EBITDA	211	144	416	176	495
Margin, %	11.4	7.5	7.9	3.1	6.0
Depreciation, amortization and write-downs of intangible assets and tangible assets	-145	-155	-419	-459	-622
Adjusted EBITA	66	-10	-3	-283	-127
Margin, %	3.6	-0.5	-0.1	-5.0	-1.5

1) See Note 3 for depreciation and write-downs and Note 5 for other items affecting comparability.

- The adjusted gross margin increased by 2.7 percentage points, primarily as a result of increased productivity and a favorable mix, for example, in the form of increased sales of service, while under-absorption in production is continuing to contribute negatively to the margin.
- Adjusted operating expenses fell by 7.3%. These expenses declined organically by 7.4%, compared with Q3 2020.
- Despite a decline in sales volumes, adjusted EBITA improved by SEK 76 M and the margin strengthened by 4.1 percentage points.
- Currency effects impacted sales by SEK -28 M, adjusted gross profit by SEK -13 M and adjusted EBITA by SEK -7 M.

Events in the business area

- In the quarter, Getinge acquired advanced technology for biological indicators from Verrix, an American start-up company. The acquisition is part of Getinge's acquisition agenda to strengthen the offering of consumables in sterile goods handling and follows the previous acquisition of Quadralene. The product is in the development phase and not yet commercially available.
- Getinge launched the Volista VisionNIR function for the surgical light Maquet Volista StandOP. The function consists of a system for NIR fluorescence imaging (NIR stands for Near Infrared) and is used to identify structures to be removed, such as cancer cells, without causing damage to nerves, blood vessels and other vital organs.
- In July, it was 25 years since Getinge's sterile goods management solution, T-DOC, was introduced. When the system was launched in 1996, it was the first solution in the world to enable healthcare facilities to transition from paper-based to fully digitized tracking of surgical instruments. Since then, Getinge has continued to develop T-DOC together with customers to meet the growing need for digitized health care.

Other information

Financial impact of COVID-19

The outbreak of COVID-19 was characterized by the WHO as a pandemic on March 11, 2020. In this situation, Getinge is prioritizing the health and safety of its employees and is taking measures to limit the spread of the virus by following the instructions of the relevant authorities. In addition, Getinge has made considerable efforts to enhance production capacity for ventilators and safeguard production of critical and life support products. Getinge has also worked intensively together with hospitals and pharmaceutical companies around the world to combat COVID-19 and assist in manufacturing vaccines.

Demand for ventilators and ECMO therapy products increased in the third quarter, which contributed to the order intake for the Acute Care Therapies business area increasing organically by 18.6%. The business area's other product segments, which were negatively impacted by the pandemic since non-essential surgeries were postponed, continued to recover and the order intake rose. However, the spread of the Delta variant in some parts of the US meant that growth in cardiovascular surgery products slowed slightly.

The order intake for the Life Science business area rose organically by 29.6%. This was largely due to the substantial increase in the order intake for the product categories of bioreactors and service, which were negatively affected by the COVID-19 pandemic. The order intake for Sterile Transfer products used to manufacture vaccines continued to display high growth. In Surgical Workflows – the business area that was exclusively negatively affected by the pandemic – the order intake increased organically by 24.6% and all product categories reported positive growth.

It has been possible to continue work on the installation and servicing of products without any major disruptions, and this was not negatively affected by restrictions in key markets. The production operations experienced minor problems with deliveries of components, which could be resolved without any significantly negative consequences arising. Challenging comparative figures as a result of record-breaking deliveries of ventilators in Q3 2020 contributed to a decline in sales and earnings for Acute Care Therapies. The areas of Acute Care Therapies that are not directly linked to treating patients with COVID-19, and that were negatively impacted by the pandemic, continued to recover, although growth in cardiovascular surgery products softened due to the spread of the Delta variant in the US.

Life Science's sales and earnings were positively impacted by higher sales growth in the product categories of Sterile Transfer, bioreactors and washer-disinfectors. Sales for Surgical Workflows declined due to long lead times between orders and deliveries. Despite lower sales volumes, earnings improved as a result of productivity enhancements.

As time passes, the situation regarding the pandemic could result in negative financial effects due to lower demand and disruptions to production. It also cannot be ruled out that installation and service of products at hospitals and care facilities could be limited by restrictions to reduce the spread of the virus. The Group's cash flow could decline due to inventory build-up and impaired payment discipline among the Group's customers. Getinge is closely following developments regarding the pandemic and is continuously evaluating the operational and financial effects. Some minor measures to adjust costs were carried out and plans have been made to further adjust costs if necessary.

For 2021, Getinge estimates that sales will amount to a minimum of SEK 27 billion. Information about Getinge's outlook for the next few years will be presented at the Capital Markets Day on November 22.

Update regarding Consent Decree with the FDA

SEK M	September 30 2021	September 30 2020	December 31 2020
Provision at beginning of period	89	234	234
Used amount	-52	-98	-136
Provisions	-	-	-
Translation differences	1	2	-9
Provision at close of period	38	138	89

At the end of quarter, Getinge completed its remediation measures in Hechingen, Germany, in accordance with the Consent Decree with the FDA. This does not automatically mean that Getinge is out of the Consent Decree, but that all entities covered by the Consent Decree (Hechingen and Rastatt in Germany and Merrimack and Wayne in the US) now can put all their efforts into forward-looking activities to add customer value and growth. However, a number of costs are expected to arise in the fourth quarter of 2021 and are expected to be covered by existing reserves according to the table above.

In autumn 2018 and the start of 2019, Getinge's production sites in Fairfield and Mahwah received warning letters from the FDA. The reason for the warning letters was routine inspections performed by the FDA at these production sites in 2018. The FDA's observations and opinions pertain to procedures and processes linked to demands for supplier checks, processes for the approval of design changes and incident reporting. The same observations were identified by Getinge during internal inspections in the fourth quarter of 2017. The local organization has since worked to correct the shortcomings in the quality management system. Getinge has submitted an action plan, including activities and a related schedule, to the FDA and improvements are proceeding according to plan.

Events after the end of the reporting period

No significant events occurred after the end of the reporting period.

Getinge’s primary risks, consequences and management¹⁾

	Description	Potential consequences	Management
New competitors and new technology	Certain markets and product segments have niche players who offer solutions outside customary market behavior.	These competitors could capture market shares from more established companies such as Getinge, resulting in a negative effect on Getinge’s sales and earnings.	Getinge’s long-term strategy includes active business intelligence of the competitive landscape to react to this type of competitor. The industry is also considered to have high barriers to entry since medical devices are subject to extensive regulatory requirements.
External catastrophes (such as geopolitical risks, natural disasters, terrorism, pandemics, etc.)	These are often quickly escalating situations that affect large parts of the world, a country, a region or a specific site.	The primary consequence of this type of risk is that employees could be injured. There is also the risk of business interruptions that could have a negative impact on sales and earnings.	Active business intelligence can detect some of these risks at an early stage and the Group will then have the chance to adapt to the new situation. A process to further enhance the Group’s work on continuity risks is planned for 2021. As part of this process, scenarios based on external shocks will also be included in the risks that Getinge proactively works on.
Profitability dependent on certain products and markets	In certain cases, a relatively large share of the total profitability of a product is linked to sales in a certain market.	The consequence of such a situation is that profitability can be adversely affected if sales volumes were to decline due to a changed competitive situation in the market.	Getinge works actively to monitor profitability per product and market in order to ensure profitability over time. To reduce the sensitivity of profitability, the Group actively works on ensuring that it has the right cost level in relation to the current price levels in the market. Getinge also works actively to establish itself in new markets.
Product quality from a customer perspective	In certain cases, Getinge’s products do not meet customer expectations.	Customers experiencing shortcomings in Getinge’s product quality could choose other suppliers. This could entail a risk of lower sales and lower profitability over time.	Getinge applies a far-reaching quality process that aims to ensure a high and even level of quality to meet customers’ requirements. This is an ongoing process that results in continuous improvements. When quality fails, it is important to rapidly bring the right equipment on site to rectify the fault during the first service visit. Getinge closely monitors the “first time fix” factor of its services operations and works extensively to make improvements related to such faults or incidents.
Laws and regulations mainly on business ethics	Contraventions of competition law, anti-corruption, data privacy (GDPR) or trade restrictions.	Could lead to fines or penalties in one or more markets and have a negative impact on the Getinge brand.	Getinge has previously provided information about ongoing investigations and agreements with the authorities regarding anti-competitive procedures in the sale of medical devices in Brazil. It cannot be ruled out that any further agreements with authorities may have a material impact on the company’s financial earnings and position. Getinge has a zero tolerance policy when it comes to contraventions of this type of regulation. The Group’s Code of Conduct is very clear in this respect. The Ethics & Compliance Group staff function was expanded during the year and the head of the department has been a member of the Getinge Executive Team since 2020 to further demonstrate how highly the organization prioritizes these issues. A comprehensive training program in Getinge’s Code of Conduct is provided on an ongoing basis and the aim is for all employees to undergo training in the field every year. Getinge’s business ethics regulations also apply to external distributors who sell Getinge’s products in a large number of countries in which the Group does not have its own presence.
Digitization and innovation	Getinge’s future growth depends on the company’s ability to develop new and successful products, particularly in the area of digitization. Getinge’s ability to innovate is a very important factor in retaining and establishing leading positions for the Group’s product segments.	Innovation efforts are costly and it is not possible to guarantee that developed products will be commercially successful, which could result in impairment. In the long term, the Group’s position in the market could be negatively affected if Getinge is unsuccessful in this area.	As a means of maximizing the return on investments in research and development, the Group applies a structured selection and planning process that includes careful analyses of the market, technological progress, choice of production method and selection of subcontractors. The actual development work is also conducted in a structured manner and each project undergoes a number of fixed control points. The Group is particularly concerned with ensuring access to the right skills, retaining key individuals, being an attractive employer to recruit talent externally, and identifying and developing talent within the organization.

¹⁾ For information regarding risks related to COVID-19 and the ongoing pandemic, refer to the section on “Financial impact of COVID-19” on page 8.

Other risks of major importance to Getinge

	Description	Potential consequences	Management
Risks related to health care reimbursement systems	Political decisions can change the conditions for health care through changed reimbursement models for health care providers.	Changes to the health care reimbursement system can have a major impact on individual markets by reducing or deferring grants.	It is difficult to influence this risk since these decisions are outside the Group's control but the risk is limited by Getinge being active in a large number of geographical markets.
Quality risks from a regulatory perspective	Significant parts of Getinge's product range are covered by legislation stipulating rigorous assessments, quality control and documentation	It cannot be ruled out that Getinge's operations, financial position and earnings may be negatively impacted in the future by difficulties in complying with current regulations and requirements of authorities and control bodies or changes to such regulations and requirements.	To limit these risks to the greatest possible extent, Getinge conducts extensive work focused on quality and regulatory issues. The Group-wide Quality & Regulatory Compliance function has a representative in the Getinge Executive Team and also a representative on the management teams of each business area, and the function is represented in all R&D and production units. In addition, Getinge's sales force and service technicians receive relevant quality and regulatory training every other year to renew their certification. This is a requirement for representing Getinge. The majority of the Group's production facilities are certified according to the medical device quality standard ISO 13485 and/or the general quality standard ISO 9001. In total, the Group allocates significant resources to quality and regulatory matters in order to best manage this risk exposure, and quality is the overall priority in the Group's strategy.
Product liability risks	Health care suppliers run a risk, like other players in the health care industry, of being subject to product liability and other legal claims.	Such claims can involve large amounts and significant legal expenses. Getinge carries the customary indemnity and product liability insurance, but there is a risk that Getinge's insurance coverage may not fully cover product liability and other claims.	Getinge acts as if the Group does not have any insurance cover. The best way of managing these risks is the extensive quality-related and regulatory activities performed by the Group. Sources of potential future claims for damages are monitored through active incident reporting. Corrective and protective action (CAPA) is initiated when necessary to investigate the underlying cause and correct the product design to remedy the fault. Getinge's subsidiary Atrium Medical is subject to ongoing product liability claims regarding the company's surgical mesh products. A provision of SEK 1.8 billion was made in October 2018 to cover estimated costs. It cannot be ruled out that the outcome of the ongoing process could have a material impact on the company's financial earnings and position.
Risks related to intellectual property rights	Getinge's leading positions in many of the Group's product segments are based on patent and trademark rights. These rights could lead to disputes with competitors.	Getinge invests significant resources in product development that results in patent rights. There is a risk that the Group will be involved in costly disputes concerning such rights and thus a risk that invested resources will not generate the expected return if such a dispute is lost.	To secure returns on these investments, Getinge actively upholds its rights and monitors competitors' activities closely. If required, Getinge will protect its intellectual property rights through legal processes.
Financial risks	Getinge is exposed to a number of financial risks in its operations. Financial risks principally pertain to currency risks, interest-rate risks, and credit and counterparty risks.	Fluctuations in exchange rates and interest rates and changes in counterparties' credit profiles could adversely affect the Group's income statement and balance sheet.	Risk management is regulated by the finance policy adopted by the Board and a Treasury directive decided by the Getinge Executive Team based on the finance policy. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the treasury function. For more detailed information concerning these risks, refer to Note 28 of the 2020 Annual Report.
Information and data security	Leaks of confidential information or hacking into the Group's IT system resulting in restricted availability or interruptions of business critical systems.	Leaks of personal data could lead to high fines. Hacking into IT systems could lead to business interruptions. A loss of sensitive information may adversely affect confidence in the company.	The Group's IT structure can be considered to be decentralized, which reduces the consequence of any unauthorized access. The Group improved user authentication during the year to prevent hacking. This work will continue in the year ahead. The Group also closely monitors critical systems to prevent hacking.
Deficiencies in cyber security	Security deficiencies in the Group's digital offering, such as connected machines at customer sites.	Restricted availability of equipment delivered by Getinge to its customers, which could result in interruptions to the hospital operations and it not being possible to offer patients sufficient care in critical situations.	Getinge works diligently to ensure the integrity of its equipment that is connected to the Internet. In-depth access testing and other measures are carried out before these solutions are offered to the Group's customers. This is considered to be a low risk for most products today since the products are not connected when patients are treated and sensitive information is seldom processed by the products.

Business interruptions

Unforeseen and sudden events, such as natural disasters, pandemics, fires, etc. that result in disruptions to production or the supply chain.

Potential interruptions and higher costs in the supply chain and production could lead to more costly or delayed deliveries or, in a worst case scenario, non-delivery to Getinge's customers. Such a situation risks negative consequences for the Group's earnings.

In the second half of 2021, there is a higher risk of temporary business interruptions linked to further delays to lower global availability of electronic components as a result of the ongoing pandemic. The Group continuously works on claims prevention to ensure a high level of availability and delivery reliability. External experts inspect the Group's production units on a regular basis to identify and take action on potential interruption risks, following a Group-wide standard. Activities to further strengthen the Group's continuity work will be conducted in 2021 and 2022.

Seasonal variations

Getinge's sales and earnings are affected by seasonal variations. The highest net sales are usually generated in the fourth quarter, followed by the second, third and first quarters. The shares of sales derived from capital goods and consumables also normally changes during the year, with a higher share of sales of capital goods toward the end of the year.

Transactions with related parties

Getinge carried out normal commercial transactions with Arjo (which was distributed to shareholders in December 2017) for the sale and purchase of goods and services. In addition, no other significant transactions with related parties occurred during the period other than transactions with subsidiaries.

Forward-looking information

This report contains forward-looking information based on the current expectations of company management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding finances, market and competition, changes in legal and regulatory requirements and other political measures, and fluctuations in exchange rates.

Getinge's financial targets and dividend policy

- Average annual organic growth in net sales: 2-4%
- Average earnings per share growth: >10%
- Getinge's dividend policy is to pay dividends of 30-50% of net profit to shareholders.

Nomination Committee ahead of 2022 Annual General Meeting

Ahead of the Annual General Meeting, the Nomination Committee shall, in accordance with the principles adopted at the 2020 Annual General Meeting, be composed of members appointed by the four largest shareholders in terms of voting rights, based on a list of owner-registered shareholders from Euroclear Sweden AB or other reliable ownership information, as of August 31 of each year, and the Chairman of the Board of Directors. In addition, if the Chairman of the Board in consultation with the member appointed by the largest shareholder in terms of voting rights deems it appropriate, it shall include an, in relation to the company and its major shareholders, independent representative of the minority shareholders as a member of the Nomination Committee.

Getinge's Nomination Committee ahead of the 2022 Annual General Meeting has been appointed and comprises the company's Chairman Johan Malmquist, and representatives from the following owners, listed by size.

- **Carl Bennet AB:** Carl Bennet
- **Fourth Swedish National Pension Fund:** Per Colleen
- **AMF Pension & Fonder** Peter Guve
- **SHB Fonder & Liv:** Anna Sundberg
- **Representing minority shareholders:** Sophie Nachemson-Ekwall

Shareholders who would like to submit proposals to Getinge's 2022 Nomination Committee can contact the Nomination Committee by e-mail at valberedningen@getinge.com or by mail: Getinge AB, Att: Nomination Committee, Box 8861, SE-402 72 Gothenburg, Sweden.

2022 Annual General Meeting

Getinge AB's Annual General Meeting will be held on April 26, 2022 in Kongresshallen at Hotel Tylösand in Halmstad, Sweden. Shareholders wishing to have a matter addressed at the Annual General Meeting can submit their proposal to Getinge's Board Chairman by e-mail: arenden.bolagsstamma@getinge.com, or by mail: Getinge AB, Att: Bolagsstämмоärenden, Box 8861, SE-402 72 Gothenburg, Sweden. To ensure inclusion in the notice and the agenda, proposals must be received by the company not later than March 8, 2022.

Assurance

The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.

Gothenburg, October 20, 2021

Johan Malmquist
Chairman,
AGM-elected Board member

Carl Bennet
Vice Chairman,
AGM-elected Board member

Johan Bygge
AGM-elected Board member

Cecilia Daun Wennborg
AGM-elected Board member

Barbro Fridén
AGM-elected Board member

Dan Frohm
AGM-elected Board member

Sofia Hasselberg
AGM-elected Board member

Rickard Karlsson
Board member
Representative of the Swedish
Metalworkers' Union

Åke Larsson
Board member
Representative of the Swedish
Association of Graduate
Engineers

Mattias Perjos
President & CEO,
AGM-elected Board member

Malin Persson
AGM-elected Board member

Kristian Samuelsson
AGM-elected Board member

AUDITOR'S REPORT

INTERIM REPORT PREPARED IN ACCORDANCE WITH IAS 34 AND CHAPTER 9 OF THE SWEDISH ANNUAL ACCOUNTS ACT

Introduction

We have reviewed the condensed interim financial information (interim report) of Getinge AB (publ) as of 30 September 2021 and the nine-month period then ended. The board of directors and the CEO are responsible for the preparation and presentation of the interim financial information in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410, Review of Interim Report Performed by the Independent Auditor of the Entity. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing, ISA, and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act, regarding the Group, and with the Swedish Annual Accounts Act, regarding the Parent Company.

Gothenburg, October 20, 2021

Öhrlings PricewaterhouseCoopers AB

Peter Nyllinge
Authorized Public Accountant
Auditor in Charge

Karin Olsson
Authorized Public Accountant

Consolidated financial statements

Consolidated income statement

SEK M	Note	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Net sales	2	6,306	7,976	19,061	20,980	29,819
Cost of goods sold		-3,173	-3,846	-9,421	-10,416	-15,097
Gross profit	2, 3	3,133	4,130	9,640	10,564	14,722
Selling expenses		-1,100	-1,203	-3,326	-3,883	-5,285
Administrative expenses		-817	-845	-2,503	-2,639	-3,498
Research and development costs		-200	-207	-617	-759	-1,033
Acquisition expenses		-3	-2	-15	-4	-8
Restructuring costs		6	0	-85	-168	-169
Other operating income and expenses		76	40	165	64	55
Operating profit (EBIT)	2, 3	1,094	1,913	3,259	3,175	4,784
Net financial items	2	-43	-72	-147	-230	-299
Profit after financial items	2	1,052	1,841	3,112	2,944	4,485
Taxes		-285	-446	-887	-775	-1,213
Net profit for the period		767	1,395	2,225	2,169	3,273
Attributable to:						
Parent Company shareholders		757	1,380	2,198	2,145	3,239
Non-controlling interests		10	15	27	24	34
Net profit for the period		767	1,395	2,225	2,169	3,273
Earnings per share, SEK ¹⁾		2.78	5.07	8.07	7.88	11.89
Weighted average number of shares for calculation of earnings per share (000s)		272,370	272,370	272,370	272,370	272,370

1) Before and after dilution

Consolidated statement of comprehensive income

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Net profit for the period	767	1,395	2,225	2,169	3,273
Other comprehensive income					
Items that cannot be restated in profit for the period					
Actuarial gains/losses pertaining to defined-benefit pension plans	0	-158	140	-108	-13
Tax attributable to items that cannot be restated in profit	0	42	-33	24	-1
Items that can later be restated in profit for the period					
Translation differences and hedging of net investments	530	-584	1,125	-615	-2,319
Cash flow hedges	-3	46	-26	-35	-16
Tax attributable to items that can be restated in profit	-6	4	-11	24	21
Other comprehensive income for the period, net after tax	522	-650	1,195	-711	-2,327
Total comprehensive income for the period	1,288	744	3,421	1,458	946
Comprehensive income attributable to:					
Parent Company shareholders	1,277	732	3,391	1,437	936
Non-controlling interests	11	12	29	22	9
Total comprehensive income for the period	1,288	744	3,421	1,458	946

Consolidated balance sheet

SEK M	Note	September 30 2021	September 30 2020	December 31 2020
Assets				
Intangible assets		23,007	23,835	22,085
Tangible assets		2,990	3,061	2,956
Right-of-use assets		1,063	974	1,017
Financial assets		1,186	1,402	1,526
Inventories		5,028	5,737	4,513
Accounts receivable		3,844	5,346	5,338
Other current receivables		1,635	2,156	1,524
Cash and cash equivalents	6	4,654	5,716	6,056
Total assets		43,408	48,227	45,014
Equity and liabilities				
Equity		24,033	22,001	21,486
Provisions for pensions, interest-bearing	6	3,234	3,626	3,359
Lease liabilities	6	1,039	947	990
Other interest-bearing liabilities	6	4,516	11,089	9,216
Other provisions		3,214	3,280	3,115
Accounts payable		1,612	1,943	1,446
Other non-interest-bearing liabilities		5,761	5,341	5,402
Total equity and liabilities		43,408	48,227	45,014

Changes in equity for the Group

SEK M	Share capital	Other capital provided	Reserves ¹⁾	Retained earnings	Total	Non-controlling interests	Total equity
Opening balance at January 1, 2020	136	6,789	1,965	11,606	20,496	477	20,973
Total comprehensive income for the period	-	-	-2,288	3,225	936	9	946
Dividend	-	-	-	-409	-409	-24	-433
Closing balance at December 31, 2020	136	6,789	-323	14,422	21,024	462	21,486
Opening balance at January 1, 2021	136	6,789	-323	14,422	21,024	462	21,486
Total comprehensive income for the period	-	-	1,085	2,306	3,391	29	3,421
Dividend	-	-	-	-817	-817	-24	-841
Transactions with non-controlling interests	-	-	-	-	-	-32	-32
Closing balance at September 30, 2021	136	6,789	762	15,911	23,598	435	24,033

1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences

Consolidated cash flow statement

SEK M	Note	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Operating activities						
Operating profit (EBIT)		1,094	1,913	3,259	3,175	4,784
Add-back of depreciation, amortization and write-downs	3	455	540	1,349	1,830	2,467
Other non-cash items		-23	9	-93	16	60
Add-back of restructuring costs ¹⁾		-6	0	85	168	169
Paid restructuring costs		-63	-67	-163	-199	-262
Financial items		-40	-72	-152	-233	-313
Taxes paid		-163	-126	-444	-404	-553
Cash flow before changes in working capital		1,255	2,197	3,840	4,354	6,352
Changes in working capital						
Inventories		-114	-211	-400	-1,175	-544
Operating receivables		222	-198	1,521	1,035	1,121
Operating liabilities		132	-15	29	442	270
Cash flow from operating activities		1,495	1,773	4,990	4,656	7,199
Investing activities						
Acquisition of operations	8	-86	-	-120	-829	-999
Investments in intangible assets and tangible assets		-245	-215	-664	-761	-1,045
Divestment of non-current assets		130	9	308	29	53
Cash flow from investing activities		-201	-206	-476	-1,561	-1,991
Financing activities						
Change in interest-bearing liabilities		0	-1,141	-4,812	2,170	543
Depreciation of lease liabilities		-97	-91	-291	-276	-390
Change in long-term receivables		1	5	2	-8	-17
Dividend paid		-24	-424	-841	-430	-433
Cash flow from financing activities		-120	-1,650	-5,941	1,456	-297
Cash flow for the period		1,174	-83	-1,427	4,551	4,911
Cash and cash equivalents at the beginning of the period		3,468	5,850	6,056	1,254	1,254
Translation differences		12	-51	25	-89	-110
Cash and cash equivalents at the end of the period		4,654	5,716	4,654	5,716	6,056

1) Excluding write-downs on non-current assets

Note 1 Accounting policies

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company, the report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2. The accounting policies adopted are consistent with those applied for the 2020 Annual Report and should be read in conjunction with that Annual Report.

For practical reasons, the figures in this interim report have not been rounded off, which is why notes and tables may not total correct amounts. Unless otherwise specified, all figures pertain to SEK M and figures in parentheses pertain to the year-earlier period. The interim report provides alternative performance measures for monitoring the Group's operations.

Note 2 Segment overview

	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Net sales, SEK M					
Acute Care Therapies	3,592	5,310	11,297	13,327	18,719
Life Science	866	746	2,515	2,048	2,854
Surgical Workflows	1,847	1,920	5,250	5,605	8,246
Total	6,306	7,976	19,061	20,980	29,819
Gross profit, SEK M					
Acute Care Therapies	2,068	3,162	6,665	7,849	10,861
Life Science	366	297	1,028	799	1,102
Surgical Workflows	699	670	1,947	1,917	2,759
Total	3,133	4,130	9,640	10,564	14,722
Operating profit (EBIT), SEK M					
Acute Care Therapies	910	1,889	3,126	3,672	5,312
Life Science	201	130	487	261	337
Surgical Workflows	62	-15	-80	-486	-489
Group functions and other (incl. eliminations) ¹⁾	-79	-90	-275	-272	-375
Operating profit (EBIT)	1,094	1,913	3,259	3,175	4,784
Net financial items	-43	-72	-147	-230	-299
Profit after financial items	1,052	1,841	3,112	2,944	4,485

1) Group functions and other refer mainly to central functions such as finance, communication, HR and other items, such as eliminations

Note 3 Depreciation, amortization and write-downs

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Acquired intangible assets	-68	-113	-201	-401	-494
Intangible assets	-167	-216	-495	-759	-1,069
Right-of-use assets	-101	-94	-300	-287	-405
Tangible assets	-119	-117	-353	-383	-500
Total	-455	-540	-1,349	-1,830	-2,467
<i>of which write-downs</i>	<i>-5</i>	<i>-7</i>	<i>-6</i>	<i>-174</i>	<i>-257</i>

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Cost of goods sold	-201	-248	-602	-749	-1,017
Selling expenses	-129	-173	-380	-590	-754
Administrative expenses	-111	-106	-331	-320	-433
Research and development costs	-14	-12	-36	-171	-263
Restructuring costs	-	-	-	-	-
Total	-455	-540	-1,349	-1,830	-2,467
<i>of which write-downs</i>	<i>-5</i>	<i>-7</i>	<i>-6</i>	<i>-174</i>	<i>-257</i>

Note 4 Quarterly results

SEK M	Jul-Sep 2021	Apr-Jun 2021	Jan-Mar 2021	Oct-Dec 2020	Jul-Sep 2020	Apr-Jun 2020	Jan-Mar 2020	Oct-Dec 2019
Net sales	6,306	6,587	6,169	8,839	7,976	6,971	6,033	8,498
Cost of goods sold	-3,173	-3,160	-3,089	-4,681	-3,846	-3,513	-3,057	-4,442
Gross profit	3,133	3,427	3,080	4,158	4,130	3,458	2,976	4,056
Operating expenses	-2,038	-2,222	-2,120	-2,548	-2,217	-2,701	-2,470	-2,579
Operating profit (EBIT)	1,094	1,205	960	1,610	1,913	757	505	1,477
Net financial items	-43	-48	-56	-69	-72	-80	-78	-112
Profit after financial items	1,052	1,157	903	1,541	1,841	677	427	1,365
Taxes	-285	-351	-251	-437	-446	-179	-150	-455
Net profit for the period	767	806	652	1,104	1,395	497	277	910

Note 5 Adjustment items

Adjusted EBITA, SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Acute Care Therapies	963	1,990	3,243	4,178	5,831
Life Science	207	136	508	281	393
Surgical Workflows	66	-10	-3	-283	-127
Group functions and other (incl. eliminations)	-76	-88	-259	-269	-374
Total	1,160	2,028	3,489	3,907	5,724

Adjustments of EBITA, SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Specification of items affecting comparability that impact EBITA					
Acquisition and restructuring costs, Acute Care Therapies	5	1	-19	-54	-62
Acquisition and restructuring costs, Life Science	1	0	-2	0	0
Acquisition and restructuring costs, Surgical Workflows	0	-1	-64	-115	-113
Write-down of R&D, Acute Care Therapies ²⁾	-	-	-	-73	-73
Write-down of R&D, Life Science ²⁾	-	-	-	-	-29
Write-down of R&D, Surgical Workflows ²⁾	-	-	-	-63	-108
Impairment of receivables, Acute Care Therapies ³⁾	-	-	-	-	-47
Impairment of receivables, Acute Care Therapies ²⁾	-	-	-	-	-8
Impairment of receivables, Surgical Workflows ²⁾	-	-	-	-	-7
Write-down of inventories, Acute Care Therapies ¹⁾	-	-	-	-	-38
Write-down of inventories, Life Science ¹⁾	-	-	-	-	-1
Write-down of inventories, Surgical Workflows ¹⁾	-	-	-	-	-92
Restored unutilized provision, Acute Care Therapies ³⁾	-	-	-	-	183
Capital gain on divestment of property, Acute Care Therapies ³⁾	-	-	72	-	-
Other, Acute Care Therapies ¹⁾	-	-	-	-2	-2
Other, Surgical Workflows ¹⁾	-	-	-	-3	-3
Other, Acute Care Therapies ²⁾	-	-	-	-7	-17
Other, Surgical Workflows ²⁾	-	-	-	-11	-18
Other, Surgical Workflows ³⁾	-	-	-	-	-8
Group functions and other (incl. eliminations)	-3	-2	-15	-4	-2
Total	3	-2	-28	-331	-446
Items affecting comparability per segment					
Acute Care Therapies	5	1	53	-135	-65
Life Science	1	0	-2	0	-30
Surgical Workflows	0	-1	-64	-192	-349
Group functions and other (incl. eliminations)	-3	-2	-15	-4	-2
Total	3	-2	-28	-331	-446

1) Reported in Cost of goods sold

2) Reported in Operating expenses

3) Reported in Other operating income and operating expenses

EBITA, SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Acute Care Therapies	968	1,991	3,296	4,042	5,766
Life Science	208	136	506	281	363
Surgical Workflows	66	-12	-67	-475	-476
Group functions and other (incl. eliminations)	-79	-90	-275	-272	-375
Total	1,163	2,026	3,460	3,576	5,278

Adjustments of EBIT (in addition to the above adjustments of EBITA), SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Specification of items affecting comparability that impact EBIT but not EBITA					
Write-down of acquired intangible assets, Acute Care Therapies ¹⁾	-	-	-	-31	-31
Total, Group	-	-	-	-31	-31

1) Reported in Operating expenses

Adjustments of EBIT, SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Items affecting comparability that impact EBITA (according to above)	3	-2	-28	-331	-446
Items affecting comparability that impact EBIT but not EBITA (according to above)	-	-	-	-31	-31
Total	3	-2	-28	-362	-477

Adjustment of tax, SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Amortization and write-down of acquired intangible assets ¹⁾	68	113	201	370	463
Items affecting comparability	-3	2	28	362	477
Adjustment items, total	66	115	230	733	940
Tax effect on adjustment items ²⁾	-17	-32	-64	-194	-248
Adjustment for tax items affecting comparability	-	-	-	-	-
Total	-17	-32	-64	-194	-248

1) Excluding write-downs classified as items affecting comparability

2) Tax effect on tax deductible adjustment items

Note 6 Consolidated net interest-bearing debt

SEK M	September 30 2021	September 30 2020	December 31 2020
Other interest-bearing liabilities, current	1,180	3,494	2,196
Other interest-bearing liabilities, long-term	3,336	7,595	7,020
Provisions for pensions, interest-bearing	3,234	3,626	3,359
Lease liabilities	1,039	947	990
Interest-bearing liabilities	8,788	15,662	13,565
Less cash and cash equivalents	-4,654	-5,716	-6,056
Net interest-bearing debt	4,134	9,946	7,509

Note 7 Key figures for the Group

	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Financial and operative key figures					
Key figures based on Getinge's financial targets					
Organic growth in net sales, %	-20.1	33.4	-2.8	15.9	14.3
Earnings per share ¹⁾ , SEK	2.78	5.07	8.07	7.88	11.89
Other operative and financial key figures					
Organic growth in order intake, %	21.8	-5.3	-5.8	19.1	15.6
Gross margin, %	49.7	51.8	50.6	50.4	49.4
Selling expenses, % of net sales	17.4	15.1	17.4	18.5	17.7
Administrative expenses, % of net sales	13.0	10.6	13.1	12.6	11.7
Research and development costs, % of net sales	4.5	3.7	4.6	5.1	4.9
Operating margin, %	17.4	24.0	17.1	15.1	16.0
EBITDA, SEK M	1,549	2,453	4,608	5,005	7,251
Average number of shares, thousands	272,370	272,370	272,370	272,370	272,370
Number of shares at the end of the period, thousands	272,370	272,370	272,370	272,370	272,370
Interest-coverage ratio, multiple			41.0	25.3	30.5
Net debt/equity ratio, multiple			0.17	0.45	0.35
Net debt/Rolling 12m adjusted EBITDA, multiple			0.6	1.4	1.0
Operating capital, SEK M			29,194	33,575	32,374
Return on operating capital, %			17.2	15.1	16.3
Return on equity, %			14.7	14.3	15.1
Equity/assets ratio, %			55.4	45.6	47.7
Equity per share, SEK			88.24	80.78	78.88
Number of employees			10,667	10,800	10,818

1) Before and after dilution

Alternative performance measures

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. Accordingly, the alternative performance measures should be considered a supplement to the financial statements prepared in accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies.

	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Adjusted gross profit, SEK M					
Gross profit	3,133	4,130	9,640	10,564	14,722
<i>Add-back of:</i>					
Depreciation, amortization and write-downs of intangible assets and tangible assets	201	248	602	749	1,017
Other items affecting comparability	-	-	-	5	135
Adjustment for write-downs included in other items affecting comparability	-	-	-	-	-
Adjusted gross profit	3,334	4,378	10,242	11,318	15,874

	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Adjusted EBITDA, SEK M					
Operating profit (EBIT)	1,094	1,913	3,259	3,175	4,784
<i>Add-back of:</i>					
Depreciation, amortization and write-downs of intangible assets and tangible assets	387	427	1,147	1,429	1,973
Amortization and write-down of acquired intangible assets	68	113	201	401	494
Other items affecting comparability	-	-	-72	23	59
Acquisition and restructuring costs	-3	2	100	172	177
Adjustment for write-downs included in other items affecting comparability and restructuring costs	-	-	-	-	-
Adjusted EBITDA	1,547	2,455	4,636	5,200	7,487

	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Adjusted EBITA, SEK M					
Operating profit (EBIT)	1,094	1,913	3,259	3,175	4,784
<i>Add-back of:</i>					
Amortization and write-down of acquired intangible assets	68	113	201	401	494
Other items affecting comparability	-	-	-72	159	269
Acquisition and restructuring costs	-3	2	100	172	177
Adjustment for write-downs of acquired intangible assets included in other items affecting comparability and restructuring costs	-	-	-	-	-
Adjusted EBITA	1,160	2,028	3,489	3,907	5,724

	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Adjusted EBIT, SEK M					
Operating profit (EBIT)	1,094	1,913	3,259	3,175	4,784
<i>Add-back of:</i>					
Other items affecting comparability	-	-	-72	190	300
Acquisition and restructuring costs	-3	2	100	172	177
Adjusted EBIT	1,092	1,915	3,287	3,537	5,261

	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Adjusted net profit for the period, SEK M					
Net profit for the period	767	1,395	2,225	2,169	3,273
<i>Add-back of:</i>					
Amortization and write-down of acquired intangible assets	68	113	201	401	494
Other items affecting comparability	-	-	-72	190	300
Acquisition and restructuring costs	-3	2	100	172	177
Adjustment for write-downs of acquired intangible assets included in other items affecting comparability and restructuring costs	-	-	-	-31	-31
Tax items affecting comparability	-	-	-	-	-
Tax on add-back items	-17	-32	-64	-194	-248
Adjusted net profit for the period	815	1,478	2,392	2,707	3,965

Note 8 Acquisitions

Acquisitions in 2021

In September 2021, Getinge acquired development activities regarding biological indicators from Verrix, an American start-up company. The products are in a development phase and are not yet commercially available, but are intended to strengthen the Group's offering in sterile goods handling in the long term. The purchase price amounted to SEK 202 million, of which SEK 127 million pertains to goodwill, which mainly relates to strategic benefits in the form of growth opportunities and a broadened product range. The costs for the acquisition amounted to SEK 3 million and have been charged to earnings. At the time of publication of this report, the acquisition analysis was still preliminary.

In the first quarter of 2021, Getinge acquired shares in the subsidiary Pulsion Medical Systems SE for SEK 32 M from non-controlling interests. In addition, SEK 2 M was paid due to adjustments of working capital related to the acquisition of Quadralene Holdings Ltd, which was acquired in 2020.

Parent Company financial statements

Parent Company's income statement

SEK M	Jul-Sep 2021	Jul-Sep 2020	Jan-Sep 2021	Jan-Sep 2020	Jan-Dec 2020
Administrative expenses	-4	-35	-10	-82	-58
Other operating income and expenses	-	0	-	38	38
Operating profit	-4	-35	-10	-44	-20
Result from participations in Group companies	1,823	19	1,823	53	308
Interest income and other similar income ¹⁾	1	0	1	0	1
Interest expenses and other similar expenses ¹⁾	-78	-41	-203	-351	-394
Profit after financial items	1,742	-57	1,611	-342	-105
Appropriations	-	-	-	-	243
Taxes	0	5	-5	56	-22
Net profit/loss for the period²⁾	1,742	-52	1,606	-286	116

1) Interest income and other similar income and interest expenses and other similar expenses include exchange-rate gains and losses attributable to the translation of financial receivables and liabilities measured in foreign currencies

2) Comprehensive income for the period corresponds to net profit for the period

Parent Company's balance sheet

SEK M	September 30 2021	September 30 2020	December 31 2020
Assets			
Intangible assets	16	26	24
Tangible assets	5	6	6
Participations in Group companies	28,855	28,493	28,090
Deferred tax assets	109	175	106
Receivables from Group companies	167	78	295
Current receivables	81	66	28
Cash and cash equivalents	1,000	894	950
Total assets	30,233	29,738	29,499
Equity and liabilities			
Equity	21,808	20,617	21,019
Long-term liabilities	570	-	-
Other provisions	31	55	32
Current liabilities to Group companies	7,592	6,398	6,932
Current liabilities	232	2,668	1,516
Total equity and liabilities	30,233	29,738	29,499

Definitions

Financial terms

Operating capital: Average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

Return on operating capital: Rolling 12 months' adjusted EBIT in relation to operating capital.

Return on equity: Rolling 12 months' profit after tax in relation to average equity.

Gross margin: Gross profit in relation to net sales.

Adjusted gross profit: Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.

EBIT: Operating profit.

Adjusted EBIT: Operating profit (EBIT) with add-back of acquisition and restructuring costs and other items affecting comparability.

EBITA: Operating profit (EBIT) before add-back of amortization and write-down of acquired intangible assets.

Adjusted EBITA: EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.

EBITA margin: EBITA in relation to net sales.

EBITDA: Operating profit (EBIT) with add-back of amortization, depreciation and write-downs.

Adjusted EBITDA: EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.

EBITDA margin: EBITDA in relation to net sales.

Equity per share: Equity in relation to the number of shares at the end of the period.

Cash flow after net investments: Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations.

Consumables: Products that are continuously consumed as well as service, spare parts and similar items.

Adjusted earnings per share: Adjusted net profit for the period attributable to Parent Company shareholders in relation to average number of shares.

Items affecting comparability: Comprises acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write-downs, disputes and major gains and losses attributable to divestments of assets or businesses.

Capital goods: Durable products that are not consumed when used.

Net debt/equity ratio: Net interest-bearing debt in relation to equity.

Organic change: A financial change adjusted for currency, acquisitions and divestments of businesses.

Adjusted net profit for the period: Net profit for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income-statement items.

Adjusted profit before tax: Profit before tax for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.

Earnings per share: Net profit attributable to Parent Company shareholders in relation to average number of shares.

Interest-coverage ratio: Rolling 12 months' adjusted EBITDA in relation to rolling 12 months' net interest.

Operating margin: Operating profit (EBIT) in relation to net sales.

Equity/assets ratio: Equity in relation to total assets.

Currency transaction effect: Exchange of current year's volumes of foreign currency at this year's exchange rates, compared with the exchange rates in the preceding year.

Medical terms

Sterilizer: A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam.

DPTE BetaBag®: Bag that ensures contamination-free transfer of components.

ECMO: Extracorporeal membrane oxygenation, meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine that exchanges oxygen and carbon dioxide, like an artificial lung.

Endoscope: Equipment for visual examination of the body's cavities, such as the stomach.

Endovascular: Vascular treatment using catheter technologies.

EU MDR: A new regulatory framework for medical devices which ensures a high level of safety and health whilst supporting innovation.

Hemodynamic monitoring: Monitoring the balance between blood pressure and blood flow.

Cardiopulmonary: Pertaining or belonging to both heart and lung.

Cardiovascular: Pertaining or belonging to both heart and blood vessels.

Artificial grafts: Artificial vascular implants.

Low temperature sterilization: A device used to sterilize surgical instruments which cannot be sterilized with high temperature steam. It is mainly used for instruments used in the minimal invasive and robotic surgery.

NAVA: Neurally Adjusted Ventilatory Assist (NAVA) identifies the electric activity that activates the diaphragm and using these signals adapts the ventilation to the patient's respiratory rhythm.

Stent: A tube for endovascular widening of blood vessels.

Vascular intervention: A medical procedure conducted through vascular puncturing instead of using an open surgery method.

Ventilator: Medical device to help patients breath.

Geographic areas

Americas: North, South and Central America.

APAC: Asia and Pacific.

EMEA: Europe, Middle East and Africa.

Teleconference

A teleconference with President & CEO Mattias Perjos and CFO Lars Sandström will be held on October 20, 2021 at 10:00-11:00 a.m. CEST. Please see dial in details below to join the conference:

SE: + 46856642692
UK: + 443333009265
US: + 16467224903

A presentation will be held during the telephone conference. To access the presentation, please use this link:
<https://tv.streamfabriken.com/getinge-q3-2021>

Alternatively, use the following link to download the presentation: <https://www.getinge.com/int/about-us/investors/reports-presentations/>

A recording will be available for three years via the following link: <https://tv.streamfabriken.com/getinge-q3-2021>

Financial information

Updated information on, for example, the Getinge share and corporate governance is available on Getinge's website www.getinge.com. The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at www.getinge.com. The preliminary dates for financial communication are provided below:

November 22, 2021 Virtual Capital Markets Day ([link](#) for more information and registration)
January 28, 2022 Q4 Report 2021

Contact

Lars Mattsson, Head of Investor Relations
+46 (0)10 335 0043
lars.mattsson@getinge.com

Jeanette Hedén Carlsson, Executive Vice President, Communications & Brand Management
+46 (0)10 335 1003
jeanette.hedencarlsson@getinge.com

This information is such that Getinge AB must disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on October 20, 2021 at 8:00 a.m. CEST.

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in 130 countries. Getinge has been listed on Nasdaq OMX Stockholm, Nordic Large Cap since 1993 and is included in the OMXS30 index of the 30 most actively traded shares.

Getinge AB (publ) | Lindholmspiren 7, 417 56 Gothenburg, Sweden | Tel: +46 (0)10 335 0000 | E-mail: info@getinge.com |
Corp. Reg. No.: 556408-5032 | www.getinge.com